DUBLIN--(http://www.researchandmarkets.com/research/wb8d3d/diabetic_gastropar) has announced the addition of GlobalData's new report "Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.)--Research and Markets (
“Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”
New Treatments Needed to Support Rising Prevalence of Diabetic Gastroparesis
The drug pipeline for the treatment of diabetic gastroparesis is not strong enough to support the ever-growing prevalence of the disease, leaving room for new market entrants, a new report by business intelligence provider GlobalData has found.
The new report* discovered a high level of unmet need in the diabetic gastroparesis therapeutics market, which can only be fulfilled by new drugs offering better efficacy and safety profiles combined with a low cost of therapy.
The prevalence of diabetes is rapidly increasing on a global scale, with numbers expected to reach 366 million by 2030. Approximately 5-12% of diabetes patients suffer from gastroparesis, indicating that an increase in the prevalence of diabetes will subsequently increase cases of gastroparesis. This will result in an increased usage of drug therapy, which will in turn create opportunities for companies to increase their offering in the growing diabetic gastroparesis market.
GlobalData found that the existing treatment options for diabetic gastroparesis are not meeting market demand and that there is a high level of unmet need in terms of safety and efficacy. The market is currently served by metoclopramide, including the generic version and the oral disintegrating tablet (ODT) formulation of metoclopramide (Metozolv ODT), and other off-label therapies such as erythromycin, Botox and cisapride. Metoclopramide carries a black box warning due to serious adverse drug reaction (tardive dyskinesia), while off-label drugs such as cisapride are no longer available in the US because of associated safety concerns.
Furthermore, the diabetic gastroparesis pipeline is weak, with only five molecules in total and all of them in the early stages of clinical development (either Phase I or II). These pipeline molecules are therefore unlikely to impact the future market until at least the next decade.
- Tranzyme Pharma (Tranzyme)
- Evoke Pharma
For more information visit http://www.researchandmarkets.com/research/wb8d3d/diabetic_gastropar